Skip to main content
. 2018 Jul 22;2018:8067610. doi: 10.1155/2018/8067610

Figure 1.

Figure 1

Time course of omalizumab's effect on AE-QoL score in the two patients (clear and black squares) with InH-AAE. Both patients showed a rapid response to omalizumab and during the 6-month treatment the patients were free of AE attacks. Two months after suspension one patient (black squares) had symptom recurrences and therefore was retreated with omalizumab.